473544-55-7Relevant academic research and scientific papers
Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing α1A-adrenoceptor agonist
Altenbach, Robert J.,Khilevich, Albert,Kolasa, Teodozyj,Rohde, Jeffrey J.,Bhatia, Pramila A.,Patel, Meena V.,Searle, Xenia B.,Yang, Fan,Bunnelle, William H.,Tietje, Karin,Bayburt, Erol K.,Carroll, William A.,Meyer, Michael D.,Henry, Rodger,Buckner, Steven A.,Kuk, Jane,Daza, Anthony V.,Milicic, Ivan V.,Cain, John C.,Kang, Chae H.,Ireland, Lynne M.,Carr, Tracy L.,Miller, Thomas R.,Hancock, Arthur A.,Nakane, Masaki,Esbenshade, Timothy A.,Brune, Michael E.,O'Neill, Alyssa B.,Gauvin, Donna M.,Katwala, Sweta P.,Holladay, Mark W.,Brioni, Jorge D.,Sullivan, James P.
, p. 3220 - 3235 (2007/10/03)
Structure-activity studies were performed on the α 1A-adrenoceptor (AR) selective agonist N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide (4). Compounds were evaluated for binding activity at the α1A, α1b, α1d, α2a, and α2B subtypes. Functional activity in tissues containing the α1A (rabbit urethra), α1B (rat spleen), α1D (rat aorta), and α2A (rat prostatic vas deferens) was also evaluated. A dog in vivo model simultaneously measuring intraurethral pressure (IUP) and mean arterial pressure (MAP) was used to assess the uroselectivity of the compounds. Many of the compounds that were highly selective in vitro for the α1A-AR subtype were also more uroselective in vivo for increasing IUP over MAP than the nonselective α1-agonists phenylpropanolamine (PPA) (1) and ST-1059 (2, the active metabolite of midodrine), supporting the hypothesis that greater α1A selectivity would reduce cardiovascular side effects. However, the data also support a prominent role of the α1A-AR subtype in the control of MAP.
N-[3-(1H-imidazol-4-ylmethyl)phenyl]-ethanesulfonamide (ABT-866, 1), a novel α1-adrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine
Altenbach, Robert J.,Khilevich, Albert,Meyer, Michael D.,Buckner, Steven A.,Milicic, Ivan,Daza, Anthony V.,Brune, Michael E.,O'Neill, Alyssa B.,Gauvin, Donna M.,Cain, John C.,Nakane, Masaki,Holladay, Mark W.,Williams, Michael,Brioni, Jorge D.,Sullivan, James P.
, p. 4395 - 4397 (2007/10/03)
N-[3-(1H-Imidazol-4-ylmethyl)phenyl]ethanesulfonamide (ABT-866, 1) is a novel α1 agent having the unique profile of α1A (rabbit urethra, EC50 = 0.60 μM) agonism with α1B (rat spleen, pA2 = 5.4) and α1D (rat aorta, pA2 = 6.2) antagonism. An in vivo dog model showed 1 to be more selective for the urethra over the vasculature than A-61603 (2), ST-1059 (3, the active metabolite of midodrine), and phenylpropanolamine (4).
